Reflecting on the First Attempts with Novel Payloads & What we are Doing Differently Now

8:30 am - Thursday 10th September 2026

  • What is the path to success for novel payloads, including how to navigate early assessment of payload platforms?
  • What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success?
  • Discussing the panellists’ approach to business development. What would a win/win business deal look like that focuses on payloads?

Speakers:

Chief Scientific Officer
Zymeworks
Chief Scientific Officer
CrossBridge Bio
Chief Executive Officer
Akari Therapeutics
cso
Iksuda